Ivabradine Actavis

Ivabradine, the active ingredient in Ivabradine Actavis, is a selective If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate without affecting contractility and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards and meeting stringent quality requirements.

Ivabradine is used to manage conditions related to abnormal heart rate and angina.

- Chronic stable angina: reduces the frequency of angina attacks by lowering heart rate. - Heart failure with reduced ejection fraction: improves symptoms and may lower hospitalization risk by decreasing heart rate.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Visual phosphenes (luminous phenomena) - Bradycardia (slow heart rate) - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention - Atrial fibrillation or other significant arrhythmias - Marked hypotension - Persistent visual disturbances - Myocardial ischemia worsening

Careful assessment and monitoring are required before and during therapy.

- Monitor heart rate: ensure resting heart rate >50 bpm before initiation. - Avoid in severe hepatic impairment: reduced clearance may increase exposure. - Caution in patients with sick sinus syndrome or atrioventricular block. - Do not combine with strong CYP3A4 inhibitors: risk of excessive drug levels. - Pregnancy and lactation: safety unknown; use only if clearly needed. - Store at room temperature: keep in the original container, protect from moisture and light.

Ivabradine may interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase ivabradine plasma concentrations. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin): may cause excessive bradycardia. - Verapamil: potentiate bradycardic effect and should be avoided.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine efficacy. - QT‑prolonging medications: monitor ECG for additive arrhythmic risk. - Alcohol: can enhance bradycardic response, requiring observation.